Legato Raises $12M for AI Hearing Glasses

Accepting help with hearing still asks many adults to make a public decision about a device designed to look invisible. Legato is financing a different route: put the assistance inside glasses people already expect to wear openly.

The Boston-area hearing-technology company emerged from stealth with $12M from Neotribe Ventures, Listen Ventures, and Village Global. Legato plans to bring its hearing-assistance eyewear, Legato Frames, to market in fall 2026, testing whether a different object and buying channel can change the identity attached to seeking help.

The FDA says close to 30M U.S. adults have some degree of hearing loss, while only about one-fifth of people who could benefit from a hearing aid seek intervention. Legato is financing a product and distribution strategy aimed directly at that adoption gap.

The capital gives the company room to finish development, support marketing, and prepare a hybrid online and eye-care-provider launch. It does not settle the harder questions around independent performance, all-day comfort, exact price, insurance coverage, or consumer demand.

What Legato Announced

Legato's August 26 announcement disclosed $12M in funding from Neotribe Ventures, Listen Ventures, and Village Global. The company did not identify a lead investor, formal round stage, valuation, exact close date, or previous financing history. The public record therefore supports a $12M investment, not an inferred Seed round or a newly calculated cumulative total.

Mehul Trivedi and Steve Romine founded Legato in late 2024 after building careers across audio, smart eyewear, and hearing care. Trivedi, now Legato's CEO, helped create Bose Frames and later led smart-eyewear work at EssilorLuxottica, including work on Meta Ray-Bans. Romine ran Bose's hearing-aid business and later served as COO of Audicus. Their shared history matters because Legato has to combine product disciplines that are usually sold through different channels and judged by different standards.

TechCrunch reported that the money had largely gone toward product development and marketing. Legato has not disclosed revenue, customers, unit volumes, or an exact allocation of the proceeds. The financing arrives at the point when the company must turn prototypes, patents, and product claims into a repeatable consumer experience.

Why Eyewear Changes the Adoption Problem

Traditional hearing products have spent decades getting smaller and less visible. That design logic assumes the device becomes easier to accept when other people cannot see it. Legato is testing a different proposition: hearing assistance may become easier to adopt when it is built into an object people already wear openly and choose partly for style.

That distinction is commercial as well as emotional. A person shopping for glasses already expects frames to sit on the face all day, match a personal look, and be replaced through a familiar retail or clinical routine. If hearing assistance can enter through that existing behavior, Legato may shorten the distance between recognizing a problem and purchasing a device.

The market need is real. The FDA's OTC hearing-aid guidance says close to 30M U.S. adults have some degree of hearing loss and only about one-fifth of those who could benefit seek intervention. The federal OTC category has been in effect since October 17, 2022 for adults 18 and older with perceived mild-to-moderate hearing loss. That rule lowered one access barrier, but access alone does not guarantee that a product will be worn.

How Legato Frames Work

Legato Frames place hearing-assistance technology inside the arms of the eyewear. The company says its AI system separates voices from background noise, while a dual-speaker architecture directs sound toward the wearer and limits leakage. Legato also says the design uses a proprietary acoustic system, signal-processing stack, and mechanical architecture to preserve an open-ear form factor.

The company reports four granted patents and more than 20 pending applications. A USPTO patent record independently confirms at least one Legato Audio patent covering an AI-driven open-ear audio signal-processing system. That record supports technical work around the product, but it does not independently validate the company's full patent count or every performance claim.

Federal records offer another useful boundary. An FDA establishment and device listing identifies four Legato Frames models as over-the-counter wireless air-conduction hearing aids. The listing establishes the regulatory product category. It should not be read as a customer review, a comparative efficacy judgment, or proof of all-day comfort.

Legato says its system can reduce escaped sound by 99% a few inches from the ear and deliver performance comparable to traditional hearing aids. Those figures remain company-reported until independent testing is available. For a product worn on the face, buyers will judge acoustic performance alongside weight, heat, fit, battery life, lens options, controls, appearance, and reliability.

The Distribution Strategy

Legato expects to sell Frames online and through selected U.S. eye-care providers in fall 2026. The company says the glasses will cost a fraction of traditional hearing aids and may often qualify for vision insurance when purchased through a clinic, but it has not disclosed exact pricing or coverage terms.

The eye-care channel could become part of the product rather than a simple sales outlet. Clinics already help consumers choose frames, fit lenses, process some insurance benefits, and return for adjustments. Legato is asking that channel to add hearing assistance to a relationship built around vision, style, and repeat care.

That strategy also creates execution risk. Eye-care providers need training, support, fitting workflows, and a clear explanation of where their responsibility begins and ends. Consumers need to understand what an OTC hearing aid can address and when more severe or complicated hearing loss requires a licensed hearing-health professional. A smoother buying path cannot blur those clinical boundaries.

What the $12M Has to Prove

Legato's financing supports a specific category thesis: a hearing device can become more acceptable by behaving like eyewear without surrendering the performance and responsibility expected of hearing technology. The founders bring unusually relevant experience to that handoff, and the FDA listing shows that the product is more than a design concept.

The remaining work is still substantial. Legato must manufacture multiple styles consistently, support customers across online and clinic channels, substantiate product claims, manage regulated-device expectations, and convince people to keep wearing the frames after the novelty fades. Investors have financed the moment when those disciplines stop living in separate résumés and begin sharing one product.

The first purchase will tell Legato whether the design earns attention. The ordinary second morning, when a customer reaches for the frames again, will begin to show whether the company changed the adoption problem it was built to solve.